Quick Answer
PUMA BIOTECHNOLOGY, INC. reported Diluted EPS of $0.61 per share for fiscal year 2025.
PUMA BIOTECHNOLOGY, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $0.61 | -1.6% |
| 2024 | $0.62 | +37.8% |
| 2023 | $0.45 | — |
| 2022 | $0.00 | +100.0% |
| 2021 | -$0.72 | +52.6% |
| 2020 | -$1.52 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.17 | -58.5% | +41.7% |
| June 30, 2025 | $0.12 | +233.3% | +100.0% |
| March 31, 2025 | $0.06 | +160.0% | -85.4% |
| September 30, 2024 | $0.41 | +241.7% | +555.6% |
| June 30, 2024 | -$0.09 | -280.0% | +10.0% |
| March 31, 2024 | -$0.10 | -433.3% | -183.3% |
| September 30, 2023 | $0.12 | +1300.0% | +140.0% |
| June 30, 2023 | $0.05 | -76.2% | +66.7% |
- PUMA BIOTECHNOLOGY, INC. showed a decrease of -1.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, PUMA BIOTECHNOLOGY, INC.’s diluted eps has grown by 140.1% (from $1.52 per share (loss) to $0.61 per share).
- The most recent figure is from PUMA BIOTECHNOLOGY, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: